Lung Screen Uptake Trial: results from a single lung cancer screening round
Mamta Ruparel, Samantha L. Quaife, Jennifer Dickson, Carolyn Horst, Sophie Tisi, Helen Hall, Magali N. Taylor, Asia Ahmed, Penny Shaw, Stephen Burke, May-Jan Soo, Arjun Nair, Anand Devaraj, Karen Sennett, Stephen W. Duffy, Neal Navani, Angshu Bhowmik, David Baldwin, Sam M. Janes
Abstract
The Lung Screen Uptake Trial tested a novel invitation strategy to improve uptake and reduce socioeconomic and smoking-related inequalities in lung cancer screening (LCS) participation. It provides one of the first UK-based 'real-world' LCS cohorts. Of 2012 invited, 1058 (52.6%) attended a 'lung health check'. 768/996 (77.1%) in the present analysis underwent a low-dose CT scan. 92 (11.9%) and 33 (4.3%) participants had indeterminate pulmonary nodules requiring 3-month and 12-month surveillance, respectively; 36 lung cancers (4.7%) were diagnosed (median follow-up: 1044 days). 72.2% of lung cancers were stage I/II and 79.4% of non-small cell lung cancer had curative-intent treatment.